Search

Amphastar Pharmaceuticals Inc

Closed

SectorHealthcare

23.58 -0.25

Overview

Share price change

24h

Current

Min

23.47

Max

23.8

Key metrics

By Trading Economics

Income

24M

30M

Sales

13M

184M

P/E

Sector Avg

14.148

56.432

EPS

0.8

Profit margin

16.502

Employees

1,976

EBITDA

12M

45M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-6.15% downside

Dividends

By Acuity

Next Earnings

5 lis 2026

Market Stats

By TradingEconomics

Market Cap

171M

1B

Previous open

23.83

Previous close

23.58

News Sentiment

By Acuity

40%

60%

120 / 339 Ranking in Healthcare

Amphastar Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 wrz 2026, 23:31 UTC

Amphastar Pharmaceuticals, Inc. is trading lower in after-market hours, continuing a trend of losses with the last three sessions closing lower.

16 wrz 2026, 19:43 UTC

Amphastar Pharmaceuticals, Inc. is advancing, having peaked earlier in the session, and remains above its 20-day moving average near the upper end of its one-month range.

10 wrz 2026, 20:01 UTC

Amphastar Pharmaceuticals shares are higher Thursday, despite earlier session pullbacks. No specific news was identified to explain the price movement.

8 wrz 2026, 20:01 UTC

News

Amphastar Pharmaceuticals is lower today amid a decline in the Pharmaceuticals sub-sector. Analysts recommend "Reduce," with Bank of America reiterating an “underperform” rating.

4 wrz 2026, 20:07 UTC

Amphastar Pharmaceuticals is lower today amid broader market declines following a strong jobs report, which has increased selling pressure across risk assets.

3 wrz 2026, 19:56 UTC

Amphastar Pharmaceuticals is trading roughly flat amid broader market fluctuations. Treasury yields declined following initial jobless claims data that exceeded expectations.

2 wrz 2026, 20:08 UTC

Amphastar Pharmaceuticals is advancing during Wednesday's session, despite earlier pulling back from a session high. No specific news was identified to explain the movement.

26 sie 2026, 20:08 UTC

Amphastar Pharmaceuticals is trading higher today, reflecting a broader market trend amid mixed performance following recent inflation data. The stock remains near its one-month range.

25 sie 2026, 20:07 UTC

Amphastar Pharmaceuticals is higher during Tuesday's session, reflecting a recovery after three consecutive lower finishes amid easing Treasury yields and falling oil prices.

24 sie 2026, 21:01 UTC

Amphastar Pharmaceuticals shares are lower in after-market hours, continuing a five-session decline. No specific news was identified to explain the price movement.

21 sie 2026, 19:56 UTC

Amphastar Pharmaceuticals Inc shares are lower today, despite earlier fluctuations. No specific news has been identified to explain the price movement.

20 sie 2026, 19:51 UTC

Amphastar Pharmaceuticals shares are higher, supported by a positive market environment and economic indicators showing strength in the broader economy.

19 sie 2026, 19:36 UTC

News

Barclays raised its price target on Amphastar Pharmaceuticals to $23.00, contributing to positive sentiment as shares remain well above their 20-day moving average.

18 sie 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc shares are higher today, reflecting market volatility amid rising U.S. Treasury yields and inflation concerns linked to geopolitical tensions.

17 sie 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid routine market fluctuations and concerns over slowing growth following declines in U.S. retail sales and consumer sentiment.

14 sie 2026, 20:01 UTC

Amphastar Pharmaceuticals is trading higher, rebounding from an early session low. The stock remains above its 20-day moving average despite no specific news.

12 sie 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

11 sie 2026, 19:56 UTC

News

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

10 sie 2026, 19:36 UTC

News

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

7 sie 2026, 19:51 UTC

News

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

6 sie 2026, 23:02 UTC

News

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

4 sie 2026, 19:51 UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 sie 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31 lip 2026, 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30 lip 2026, 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29 lip 2026, 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28 lip 2026, 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24 lip 2026, 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22 lip 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21 lip 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

Peer Comparison

Price change

Amphastar Pharmaceuticals Inc Forecast

Price Target

By TipRanks

-6.15% downside

12 Months Forecast

Average 22.167 USD  -6.15%

High 30 USD

Low 20 USD

Based on 6 Wall Street analysts offering 12 month price targets forAmphastar Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

0

Buy

5

Hold

1

Sell

Sentiment

By Acuity

120 / 339 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.